Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT02006472) tested four different doses of a drug called pridopidine — 45 mg, 67.5 mg, 90 mg, and 112.5 mg (each taken twice daily) — against a placebo (inactive treatment) in people with Huntington's disease. Around 408 people were enrolled across the five groups at the start of the trial, with roughly 81–82 people in each group. The trial ran in two periods: the first up to 26 weeks, and the second continuing to 52 weeks. The main thing being measured was a standardised motor (movement) score called the UHDRS Total Motor Score, which rates things like eye movement, speech, involuntary movements, balance, and gait on a scale of 0 to 124 — where a lower score means better movement ability. The reported data shows that at 26 weeks, all five groups had lower (improved) motor scores compared to where they started. The placebo group's score changed by −4.79 points on average, while the pridopidine groups changed by −3.37 (45 mg), −3.09 (67.5 mg), −4.13 (90 mg), and −2.74 (112.5 mg). Regarding adverse events (unwanted health occurrences reported during the trial), the reported data shows that 62 of 82 placebo participants, and between 63 and 71 of 81–82 participants in each pridopidine dose group, experienced at least one adverse event. For a pre-specified secondary measure of daily functioning (Total Functional Capacity, scored 0–13, where lower is worse) at 52 weeks, score changes ranged from −0.83 in the placebo group to −0.72, −0.65, and −0.59 in three of the pridopidine groups, while the 45 mg group showed a change of +0.04. Some additional post-hoc analyses (analyses planned after the trial completed) looked specifically at participants with earlier-stage Huntington's disease, but these involved only a subset of the data and their full details were not reported across all dose groups. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 36811812) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Huntington's Disease Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with Huntington's disease (HD), confirmed by a specific genetic marker (36 or more CAG repeats on a gene test)
- You are male or female, aged 21 or older, and your HD symptoms began after the age of 18
- If you are a woman who could become pregnant, you must be willing to use reliable contraception throughout the entire study
- You weigh at least 50 kg (about 110 lbs)
- Your HD symptoms and ability to function independently fall within a specific range as measured by standard HD rating scales (confirm with trial site)
- You are willing and able to sign a consent form before any study activities begin
- You are willing to give a blood sample for genetic testing
- You are able to swallow pills and willing to follow the study's specific requirements
- You are able to walk and travel to the study centre, and the doctors expect you to continue being able to do so throughout the study
- You have a caregiver, family member, or someone close to you who is willing and able to come with you to clinic visits, and the study team considers them suitable
Who may not be able to join:
- You have a significant heart condition identified at your initial screening appointment
- You have taken a medication called tetrabenazine within the 6 weeks before screening
- You have a history of epilepsy or have had a seizure in the last 5 years
- You have other serious health conditions that the study doctor believes could put you at risk, affect the study results, or affect your ability to participate
- You are currently taking, or may need to take during the study, certain medications known to affect heart rhythm — such as some antipsychotics, tricyclic antidepressants, or certain heart medications — within 6 weeks before screening (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
4 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Change From Baseline in Unified Huntington's Disease Rating Scale-Total Motor Score (UHDRS-TMS) at Week 26
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.